A JAMA Internal Medicine analysis found that 383 NIH‑funded clinical trials were disrupted after grant cancellations tied to federal funding cuts—affecting tens of thousands of participants and hundreds of cancer and infectious‑disease studies. The cancellations ranged from completed trials to studies still recruiting, raising ethical and scientific concerns about participant safety, data integrity and wasted resources. Universities are negotiating with the administration and pursuing stopgap deals to restore research funding, but scholars warn that such arrangements risk short‑changing peer review, independence and long‑term research capacity. Research leaders say restoring predictable federal research funding and clear legal protections will be essential to avoid further erosion of clinical research and investigator morale.